Artificial intelligence news.
Straight from the original announcements.

Novo reports about 21% weight loss for lower-dose CagriSema

November 14, 2026, 18:00By the AI News Bites Editorial TeamSource: PR Newswire

Novo Nordisk says its investigational CagriSema combination produced estimated average weight loss of 20.7% and 21.0% after 68 weeks at two lower doses in the REDEFINE 9 trial. The results were reported at ObesityWeek 2026 and published simultaneously in The Lancet Diabetes & Endocrinology.

Key points
  • REDEFINE 9 tested CagriSema doses of 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg.
  • Estimated average weight loss at 68 weeks was 20.7% and 21.0%, compared with 2.0% for placebo.
  • The trial included 309 adults with obesity or overweight and an obesity-related complication, without diabetes.
  • The most frequently reported adverse events were gastrointestinal and mild to moderate.
  • CagriSema is investigational and is not approved for use in the United States.

Lower doses outperformed placebo

REDEFINE 9 evaluated once-weekly CagriSema in 309 adults with obesity, or overweight and at least one obesity-related complication, without diabetes. Participants also received lifestyle intervention. The 68-week, phase 3, placebo-controlled trial compared CagriSema doses of 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg with pooled placebo.

Using the efficacy estimand, which reflects the treatment effect if all participants adhered to treatment, estimated average weight loss was 20.7% with the 1.7 mg / 1.7 mg dose and 21.0% with the 1.0 mg / 1.0 mg dose. The placebo result was 2.0%. Novo reported estimated treatment differences of −18.8 and −19.0 percentage points, with p<0.0001 for both comparisons.

The trial was not powered to detect differences between the two CagriSema doses.

Weight-loss thresholds and waist circumference

At week 68, 95.1% of participants receiving CagriSema 1.7 mg / 1.7 mg achieved at least 5% body weight loss, compared with 96.3% for the 1.0 mg / 1.0 mg dose and 33.4% for placebo. At least 10% weight loss was achieved by 87.3% and 86.0% of participants at the two CagriSema doses, compared with 13.6% for placebo.

For at least 15% weight loss, the corresponding figures were 70.5%, 70.7% and 5.8%. At least 20% weight loss was achieved by 51.3% and 48.3% of participants receiving CagriSema, compared with 2.7% for placebo.

CagriSema also reduced waist circumference by 17.2 cm with the 1.7 mg / 1.7 mg dose and 17.5 cm with the 1.0 mg / 1.0 mg dose, compared with 3.6 cm for placebo. These were statistically significant differences, according to Novo.

Safety and development status

Novo said the safety profile at both doses was consistent with previous CagriSema trials. The most frequently reported adverse events were gastrointestinal and mild to moderate in severity. Permanent treatment discontinuation occurred in 2.9% of participants receiving 1.7 mg / 1.7 mg, 4.9% receiving 1.0 mg / 1.0 mg and 4.9% receiving placebo.

CagriSema is a fixed-dose combination of the long-acting amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide. Novo filed a New Drug Application with the U.S. Food and Drug Administration in December 2025 for CagriSema 2.4 mg / 2.4 mg for weight management, with a decision expected in Q4 2026.

The medicine is not approved for use in the United States, and its safety and efficacy are not established. Novo says there is no guarantee that it will become commercially available for the uses under clinical investigation.

Novo NordiskCagriSemaREDEFINE 9ObesityWeekThe Lancet Diabetes & Endocrinologyhealthcareresearch findings

Related news

Ascletis reports preclinical results for oral and long-acting obesity drugs
ResearchNovember 16, 2026, 10:10

Ascletis reports preclinical results for oral and long-acting obesity drugs

Ascletis Pharma has presented preclinical results for an oral GLP-1R and GIPR combination and a long-acting triple agonist aimed at obesity treatment. The company said…

SAS and Posit Partner on Governed AI for Life Sciences
BusinessNovember 16, 2026, 09:00

SAS and Posit Partner on Governed AI for Life Sciences

SAS and Posit PBC have formed a partnership to give life sciences organizations more flexibility in using SAS and open-source technologies, initially for clinical…

Microsoft rebuilds Novo clinical data agent as hosted Foundry service
For developersNovember 11, 2026, 22:40

Microsoft rebuilds Novo clinical data agent as hosted Foundry service

Microsoft and Novo Nordisk have reimplemented an AI agent for secondary analysis of clinical trial data as a hosted agent in Microsoft Foundry. Microsoft says the move…